Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 3;42(9):401.
doi: 10.1007/s12032-025-02929-5.

Detecting vascular normalization in epithelial ovarian cancer

Jânio da S Mororó #  1 , Débora D Meira #  2 , Solange M D Bizzo  3 , Lorena S C Altoé  4 , Matheus C Casotti  4 , Gabriel M Santana  5 , Luana S Louro  5 , Thomas E S Louro  6 , Creuza R Vicente  7 , Bruno C de Araújo  4 , Sonia Groisman  8 , Elizeu F de Carvalho  8 , Iúri D Louro  4
Affiliations
Review

Detecting vascular normalization in epithelial ovarian cancer

Jânio da S Mororó et al. Med Oncol. .

Abstract

Epithelial ovarian cancer (EOC) is highly angiogenic, making this tumor attractive, in the last 20 years, for analysis of clinical and biological functions of the VEGF family, relating altered expression with patient's clinical responses. Currently, analyzes and validations have yet to be made to relate vascular normalization with combinations of immune-, chemo- or radiotherapy. We review the main clinical analyses capable of identifying markers of vascular normalization including functional biomarkers (e.g., perfusion parameters by imaging techniques), molecular biomarkers (e.g., circulating protein levels and cfDNA), blood biomarkers, physiological markers and other approaches. Many markers cited here have not yet been analyzed in EOC but have shown promising results in tumors such as pancreatic and glioblastoma cancer, which share similarities with ovarian cancer. The methodologies presented have the advantage of not being invasive and immediately detecting vascular normalization, mainly using imaging techniques.

Keywords: Antiangiogenic therapy; Microenvironment; Ovarian cancer; Predictive therapy biomarkers; Vascular normalization.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The author(s) declare(s) that there is no conflict of interest regarding the publication of this paper. Informed consent: The authors declare consent to publish.

References

    1. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997;80:98–106. - PubMed
    1. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994;54:276–80. - PubMed
    1. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103:512–7. - PubMed
    1. Artini P, Cristello F, Monti M, Cela V, Battaglia C, D’Ambrogio G, et al. Vascular endothelial growth factor and its soluble receptor in ovarian pathology. Gynecol Endocrinol. 2005;21:50–6. - PubMed
    1. Bizzo SMD, Meira DD, Lima JM, da Silva Mororó J, de Barros Moreira FC, Casali-da-Rocha JC, et al. Serum albumin and vascular endothelial growth factor in epithelial ovarian cancer: looking at adnexal tumor drainage. Arch Gynecol Obstet. 2011;283:855–9. - PubMed

MeSH terms

Substances

LinkOut - more resources